1-(4-Chloro-o-tolyl)piperazine → 3-{4-[4-(4-Chloro-2-methylphenyl)-piperazin-1-yl]-butyl}-3-ethyl-1,3-dihydro-2H-indol-2-one monohydrochloride
반응식
[Cl:1][CH2:2][CH2:3][CH2:4][CH2:5][C:6]1([CH2:16][CH3:17])[C:14]2[C:9](=[CH:10][CH:11]=[CH:12][CH:13]=2)[NH:8][C:7]1=[O:15].[Cl:18][C:19]1[CH:24]=[CH:23][C:22]([N:25]2[CH2:30][CH2:29][NH:28][CH2:27][CH2:26]2)=[C:21]([CH3:31])[CH:20]=1>>[ClH:1].[Cl:18][C:19]1[CH:24]=[CH:23][C:22]([N:25]2[CH2:30][CH2:29][N:28]([CH2:2][CH2:3][CH2:4][CH2:5][C:6]3([CH2:16][CH3:17])[C:14]4[C:9](=[CH:10][CH:11]=[CH:12][CH:13]=4)[NH:8][C:7]3=[O:15])[CH2:27][CH2:26]2)=[C:21]([CH3:31])[CH:20]=1참가 물질
3
실험 절차
The title compound is prepared according to process H by applying processing method 2 starting from 3-(4-chlorobutyl)-3-ethyl-1,3-dihydro-2H-indol-2-one and 1-(4-chloro-2-methyl-phenyl)-piperazine.
출처 및 근거
- ORD 기록
- ord-8746a43a58d84e629a7ad30eccf01a87
- 출처 데이터셋
- uspto-grants-2010_08